Клиническое полногеномное секвенирование на платформах MGI DNBSEQ-T7 и DNBSEQ-G400: применение методов низкопокрывного (low-pass), стандартного и глубокого (deep) полногеномного секвенирования
Clinical positioning of the DNBSEQ-G99 relative to the DNBSEQ-G400 and DNBSEQ-T7
manufacturer-stated specifications taken from the MGI G99 brochure (version 20251201) [58] and the regulatory notices cited in the text [59], [60]; all caveats on nameplate throughput stated above apply. n/s = not stated in the source used; genome counts assume ~100 Gb of raw PE150 data per 30× genome and are derived from vendor read counts, not independently measured; G99 regulatory dates are from GenomeWeb reports
Attribute | NBSEQ-G99 | DNBSEQ-G400 | DNBSEQ-T7 |
Format | Benchtop (~140 kg); 2 independent flow cells | Floor-standing; 2 flow cells | Floor-standing; 4 flow cells |
Reads per flow cell (vendor) | 40 M (FCS), 80 M (FCL), 200 M (FCU) | 300–1,800 M | ~5,800 M |
Output per run (vendor) | 8–240 Gb | 55–1,440 Gb | 1–7 Tb |
PE150 run time | ~12 h (FCL); ~16 h (FCU) | 37–88 h | 22–24 h |
Fastest mode | SE100/PE50 in ~5 h (FCL) | n/s | n/s |
Maximum read length | PE300 (App-D FCL/FCU); SE400 | PE150 (FCL); PE300 (specific kits) | PE150 |
Approx. 30× human genomes per flow cell (derived) | ≤1 (FCU PE150) | ~5 (FCL PE150) | ~15–17 |
Regulatory status (selected) | NMPA registration (Sept 2023); CE mark under IVDR, Class A self-declared (2023) | NMPA; CE-IVD (2022) | NMPA Class III (2020); CE-IVD (2022); no FDA clearance |
Vendor-recommended clinical applications | Targeted oncology panels; mNGS/pathogen detection; methylation panels; NIPT/PGS (~8–20 samples per flow cell); 16S; small genomes | NIPT (96–384 per flow cell); PGT; POC; WES; small-batch 30× WGS | 30× and deep WGS at scale; population programs; high-volume NIPT |
Role in this review’s coverage tiers | Low-pass tier and mNGS only | Low-pass and standard tiers | Standard and deep tiers |